UBI集團訊息

UBP Wins 2017 Bioprocessing Executive of the Year and Advancing Development of Innovative Bio-Molecules from Biologics Manufacturing Asia (BMA)

United BioPharma (UBP, 6471) announced that Biologics Manufacturing Asia (BMA) has honored UBP and and its president of UBP, Mei Jun Liao, Ph.D., with awards of Advancing Development of Innovative Bio-Molecules and Bioprocessing Executive of the Year, respectively.

UBP gained positive international recognition for innovative development. Dr. Liao has led UBP to develop considerable milestones, thereby easily earning the award.


About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind. 

United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.